You are now leaving this website. By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.
You are now leaving this website. By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co., Inc., Rahway, NJ, USA.
MSD Ballydine is looking for innovative thinkers to join them in inventing new products from pilot to commercial scale
Our existing portfolio and future pipeline offers Ballydine team members the opportunity to operate at the cutting-edge of science and technology, and develop new treatments that positively impact patients across the globe.
We want to tackle the world's greatest health challenges
MSD Ballydine develops and supplies the active ingredients and final formulated product for a range of innovative medicines at its manufacturing and R&D facilities. The plant, which has been operating in Tipperary for over 40 years, exports to over 25 countries around the world with primary markets being Europe, USA and Japan.
Join a team of bold dreamers, explorers and tinkerers
Our highly-skilled local workforce of 500 employees is now leading the way in the development of new medicines, including MSD’s new treatment for hepatitis C, which is being manufactured in Tipperary for patients around the world.
This site has been a vibrant part of the pharmaceutical sector in Cork for over 35 years. With a successful legacy of developing and commercially supplying biotech products, Brinny is now specialising in the development and manufacture of innovative novel vaccines and testing of immuno-oncology medicines.
Opened in 2008 as MSD’s first vaccines facility outside of the US. Carlow is the filling site for the liquid form of our immuno-oncology treatment for the global market. We are currently working on the construction of a second manufacturing facility that will focus on the production of vaccines and biologics.
The base for our Animal Health and Human Health businesses as well as a number of global and national support services including Clinical Research, Medical Affairs, Regulatory Affairs, Sales, Policy & Communications and Marketing.
This site will play a pivotal role in the manufacture of MSD’s biologics-based medicines, including in the area of immuno-oncology, and will expand MSD’s current internal network of biologics drug substance manufacturing plants when full manufacturing operations begin in 2021.
The latest addition to the MSD, Ireland family is Dunboyne which joined our network in September 2020. With a team of over 200, this site will be MSD’s first Biologics Drug Substance single use commercialization facility, playing an important role in helping us commercialise key medicines.
This careers website is intended for Residents of Europe, Middle East, Africa, Latin America & Asia Pacific. Residents in the United States, Canada & Puerto Rico, please visit this Careers website. Information on this site is for the purpose of presenting career opportunities at our organisation and give our audience a view of our culture, diversity and growth opportunities. Our Company is an equal opportunity employer, proudly embracing diversity in all of its manifestations.